DATA I/O CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DATA I/O CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.50M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $21.77M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $28.06M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $24.22M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $25.84M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $20.33M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $21.57M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $29.22M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $34.05M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $23.41M | Mar 28, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.60M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $11.61M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $16.19M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $13.21M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $14.72M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $10.82M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $12.55M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $17.36M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $20.06M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $12.87M | Mar 28, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.24M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($3.09M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $486.0K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($1.12M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($555.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.96M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.19M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.61M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.45M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.66M | Mar 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.12M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($3.04M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $448.0K | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($749.0K) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($273.0K) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($3.08M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.28M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.74M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.05M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $1.43M | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.53M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $6.24M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $6.52M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $6.08M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.64M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.36M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $6.45M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $7.36M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $6.90M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $5.07M | Mar 28, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.18M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $8.40M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $9.21M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $7.88M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $8.36M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $6.89M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $7.38M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $8.26M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.12M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $6.38M | Mar 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.23M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($995.0K) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $2.43M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($1.05M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $1.41M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $631.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($2.10M) | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.11M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $9.13M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $2.96M | Mar 28, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $558.0K | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $467.0K | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $1.20M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $1.08M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $623.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $860.0K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $612.0K | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $907.0K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.15M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $2.12M | Mar 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.18M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $24.97M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | $27.40M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | $27.17M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $29.06M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $25.59M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $28.28M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $30.72M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $30.29M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $22.78M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.51M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | $17.63M | Apr 16, 2026 |
| FY2025 | Dec 31, 2023 | $20.32M | Apr 16, 2026 |
| FY2024 | Dec 31, 2022 | $19.11M | Apr 1, 2025 |
| FY2023 | Dec 31, 2021 | $19.85M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $19.64M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $21.53M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $23.36M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $22.06M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $16.03M | Mar 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.97M) | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | ($5.74M) | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | ($2.65M) | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | ($3.13M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($2.01M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($1.46M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.51M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | $3.70M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.09M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($3.36M) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $11.51M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $14.19M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $14.17M | Mar 30, 2022 |
| FY2021 | Dec 31, 2019 | $13.94M | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | $18.34M | Mar 26, 2021 |
| FY2019 | Dec 31, 2017 | $18.54M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $11.57M | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $11.27M | Mar 28, 2018 |
| FY2016 | Dec 31, 2014 | $9.36M | Jun 26, 2017 |
| FY2015 | Dec 31, 2013 | $10.43M | Mar 28, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 28, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 28, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.39M | Apr 16, 2026 |
| FY2025 | Dec 31, 2024 | 9.24M | Apr 16, 2026 |
| FY2024 | Dec 31, 2023 | 9.02M | Apr 1, 2025 |
| FY2023 | Dec 31, 2022 | 8.82M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 8.62M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 8.42M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 8.21M | Mar 26, 2021 |
| FY2019 | Dec 31, 2018 | 8.34M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 8.28M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 8.02M | Mar 28, 2018 |